• Cat-intel
  • MedIntelliX
  • Consulting
  • Resources
  • About Us
  • News
  • Careers
  • Contact Us
  • Login
    • English
    Chinese
    French
    Hindi

    Chronic Obstructive Pulmonary Disease (COPD) Market

    ID: 1081
    90 Pages
    Research Team
    07/2025

    Chronic obstructive pulmonary disease (COPD) Market Research Report Information By CPOD Type (Emphysema, Chronic Bronchitis), By Treatment Type (Drugs, Anti-Inflammatory Drugs, Surgery, Oxygen Therapy), By End Users (Hospitals & Clinics, Homecare Settings, and Others), And By Region (North America, Europe, Asia-Pacific, And Rest Of The World) - Forecast Till 2032

    Share:
    ReportInfographic

    Purchase Options

    $ 4,950.0
    $ 5,950.0
    $ 7,250.0
    Compare License

    Market Summary

    Research Methodology on Global Chronic Obstructive Pulmonary Disease Market


    1. Introduction:


    Chronic obstructive pulmonary disease (COPD) refers to a group of chronic lung diseases that have an obstructed airflow from the lungs, including emphysema, chronic bronchitis and/or asthma. It is one of the main causes of morbidity and mortality worldwide and its increasing prevalence has led to a strong interest in research into this condition. This report presents a comprehensive overview of the latest findings in COPD and provides an understanding of the current market trends and emerging treatments. The objective of this research is to provide insights into the COPD market, by analysing the current treatments, and recent developments and assessing their future impact on the market.


    2. Literature review:


    This research involves a literature review of existing published research studies, reports and literature in the field of COPD, to identify and analyse current trends, developments and treatments available. Relevant databases such as Medline, PubMed, MedlinePlus and ScienceDirect are searched for relevant studies and reports. Relevant articles are carefully screened and those relevant to the research topic are selected based on their level of methodological rigour and relevance to the objectives of the research. Once the relevant articles are identified, the data from each study is collated, appraised and analysed for its relevance and accuracy.


    3. Data Collection and Analysis:


    The next step in this research is to collect primary data using a qualitative research approach. Semi-structured interviews are conducted with doctors and specialists, key opinion leaders, healthcare professionals and representatives of drug & device manufacturers, to understand their views on the current COPD landscape. In addition to this, patient/consumer surveys are carried out to gain insights into patient/consumer opinions and preferences when it comes to COPD treatments. The primary data collected from these interviews and surveys are analysed using thematic analysis and results are interpreted.


    4. Secondary Data Collection and Analysis:


    In addition to primary data collection, secondary data is collected from various sources such as WHO, CDC, peer-reviewed journals, and trade reports. This data is analysed to gain an understanding of the current global epidemiology and market trends. Data from the secondary sources are collated, analysed and interpreted.


    5. Findings and Recommendations:


    The results of both primary and secondary data collection and analysis are presented in a comprehensive report. This report provides an insightful overview of the COPD market, including current treatments, recent developments, trends and future outlook. Furthermore, detailed recommendations are provided to help stakeholders make informed decisions when it comes to developing and marketing new COPD treatments.

    Market Size & Forecast

    Attribute/Metric Details
    Market Size 2023 USD 20.84 billion
    Market Size 2024 USD 22.07 billion
    Market Size 2032 USD 33.72 billion
    Compound Annual Growth Rate (CAGR) 4.82% (2024-2032)
    Base Year 2023
    Forecast Period 2024-2032
    Historical Data 2018 & 2020
    Forecast Units Value (USD Billion)
    Report Coverage Revenue Forecast, Competitive Landscape, Growth Factors, and Trends
    Segments Covered Type, Treatment Type, End User and Region
    Geographies Covered North America, Europe, Asia Pacific, and Rest of the World
    Countries Covered The U.S, Canada, Germany, France, UK, Italy, Spain, China, Japan, India, Australia, South Korea, and Brazil
    Key Companies Profiled AstraZeneca (UK), Abbott Laboratories (US), Dr. Reddy’s Laboratories Ltd (India), GlaxoSmithKline (UK), F. Hoffmann-La Roche Ltd (Switzerland), Almirall (Spain), Boehringer Ingelheim (Germany), Pfizer Inc. (US), Novartis AG (Switzerland), Astellas Pharma (Japan)
    Key Market Opportunities Increasing demand for home care therapeutic devices
    Key Market Dynamics Rise in prevalence of CPOD across the globe Increase in adoption of more effective combination therapy

    Major Players

    Chronic Obstructive Pulmonary Disease (COPD) Market Segmentation Chronic obstructive pulmonary disease (COPD) Type Outlook (USD Billion, 2018-2030)

    • Emphysema

    • Chronic Bronchitis

    Chronic obstructive pulmonary disease (COPD) Treatment Outlook (USD Billion, 2018-2030)

    • Drugs

      • Bronchodilator Monotherapy

        • Short-Acting Beta2-Agonists (SABAs)

        • Long-Acting Beta2-Agonists (LABAs)

      • Anti-Inflammatory Drugs

        • Oral And Inhaled Corticosteroids

        • Anti-Leukotrienes

    • Surgery

      • Lung Volume Reduction Surgery (LVRS)

      • Lung Transplant

      • Bullectomy

      • Others

    • Oxygen Therapy

    Chronic obstructive pulmonary disease (COPD) End User Outlook (USD Billion, 2018-2030)

    • Hospitals & Clinics

    • Homecare Settings

    • Others

    Chronic obstructive pulmonary disease (COPD) Regional Outlook (USD Billion, 2018-2030)

    • North America Outlook (USD Billion, 2018-2030)

      • North America Chronic obstructive pulmonary disease (COPD) by Type

        • Emphysema

        • Chronic Bronchitis

      • North America Chronic obstructive pulmonary disease (COPD) by Treatment

        • Metal Drugs

          • Bronchodilator Monotherapy

            • Short-Acting Beta2-Agonists (SABAs)

            • Long-Acting Beta2-Agonists (LABAs)

          • Anti-Inflammatory Drugs

            • Oral And Inhaled Corticosteroids

            • Anti-Leukotrienes

        • Surgery

          • Lung Volume Reduction Surgery (LVRS)

          • Lung Transplant

          • Bullectomy

          • Others

        • Oxygen Therapy

      • North America Chronic obstructive pulmonary disease (COPD) by End User

        • Hospitals & Clinics

        • Homecare Settings

        • Others

      • US Outlook (USD Billion, 2018-2030)

      • US Chronic obstructive pulmonary disease (COPD) by Type

        • Emphysema

        • Chronic Bronchitis

      • US Chronic obstructive pulmonary disease (COPD) by Treatment

        • Metal Drugs

          • Bronchodilator Monotherapy

            • Short-Acting Beta2-Agonists (SABAs)

            • Long-Acting Beta2-Agonists (LABAs)

          • Anti-Inflammatory Drugs

            • Oral And Inhaled Corticosteroids

            • Anti-Leukotrienes

        • Surgery

          • Lung Volume Reduction Surgery (LVRS)

          • Lung Transplant

          • Bullectomy

          • Others

        • Oxygen Therapy

      • US Chronic obstructive pulmonary disease (COPD) by End User

        • Hospitals & Clinics

        • Homecare Settings

        • Others

      • Canada Outlook (USD Billion, 2018-2030)

      • Canada Chronic obstructive pulmonary disease (COPD) by Type

        • Emphysema

        • Chronic Bronchitis

      • Canada Chronic obstructive pulmonary disease (COPD) by Treatment

        • Metal Drugs

          • Bronchodilator Monotherapy

            • Short-Acting Beta2-Agonists (SABAs)

            • Long-Acting Beta2-Agonists (LABAs)

          • Anti-Inflammatory Drugs

            • Oral And Inhaled Corticosteroids

            • Anti-Leukotrienes

        • Surgery

          • Lung Volume Reduction Surgery (LVRS)

          • Lung Transplant

          • Bullectomy

          • Others

        • Oxygen Therapy

      • Canada Chronic obstructive pulmonary disease (COPD) by End User

        • Hospitals & Clinics

        • Homecare Settings

        • Others

    • Europe Outlook (USD Billion, 2018-2030)

      • Europe Chronic obstructive pulmonary disease (COPD) by Type

        • Emphysema

        • Chronic Bronchitis

      • Europe Chronic obstructive pulmonary disease (COPD) by Treatment

        • Metal Drugs

          • Bronchodilator Monotherapy

            • Short-Acting Beta2-Agonists (SABAs)

            • Long-Acting Beta2-Agonists (LABAs)

          • Anti-Inflammatory Drugs

            • Oral And Inhaled Corticosteroids

            • Anti-Leukotrienes

        • Surgery

          • Lung Volume Reduction Surgery (LVRS)

          • Lung Transplant

          • Bullectomy

          • Others

        • Oxygen Therapy

      • Europe Chronic obstructive pulmonary disease (COPD) by End User

        • Hospitals & Clinics

        • Homecare Settings

        • Others

      • Germany Outlook (USD Billion, 2018-2030)

      • Germany Chronic obstructive pulmonary disease (COPD) by Type

        • Emphysema

        • Chronic Bronchitis

      • Germany Chronic obstructive pulmonary disease (COPD) by Treatment

        • Metal Drugs

          • Bronchodilator Monotherapy

            • Short-Acting Beta2-Agonists (SABAs)

            • Long-Acting Beta2-Agonists (LABAs)

          • Anti-Inflammatory Drugs

            • Oral And Inhaled Corticosteroids

            • Anti-Leukotrienes

        • Surgery

          • Lung Volume Reduction Surgery (LVRS)

          • Lung Transplant

          • Bullectomy

          • Others

        • Oxygen Therapy

      • Germany Chronic obstructive pulmonary disease (COPD) by End User

        • Hospitals & Clinics

        • Homecare Settings

        • Others

      • France Outlook (USD Billion, 2018-2030)

      • France Chronic obstructive pulmonary disease (COPD) by Type

        • Emphysema

        • Chronic Bronchitis

      • France Chronic obstructive pulmonary disease (COPD) by Treatment

        • Metal Drugs

          • Bronchodilator Monotherapy

            • Short-Acting Beta2-Agonists (SABAs)

            • Long-Acting Beta2-Agonists (LABAs)

          • Anti-Inflammatory Drugs

            • Oral And Inhaled Corticosteroids

            • Anti-Leukotrienes

        • Surgery

          • Lung Volume Reduction Surgery (LVRS)

          • Lung Transplant

          • Bullectomy

          • Others

        • Oxygen Therapy

      • France Chronic obstructive pulmonary disease (COPD) by End User

        • Hospitals & Clinics

        • Homecare Settings

        • Others

      • UK Outlook (USD Billion, 2018-2030)

      • UK Chronic obstructive pulmonary disease (COPD) by Type

        • Emphysema

        • Chronic Bronchitis

      • UK Chronic obstructive pulmonary disease (COPD) by Treatment

        • Metal Drugs

          • Bronchodilator Monotherapy

            • Short-Acting Beta2-Agonists (SABAs)

            • Long-Acting Beta2-Agonists (LABAs)

          • Anti-Inflammatory Drugs

            • Oral And Inhaled Corticosteroids

            • Anti-Leukotrienes

        • Surgery

          • Lung Volume Reduction Surgery (LVRS)

          • Lung Transplant

          • Bullectomy

          • Others

        • Oxygen Therapy

      • UK Chronic obstructive pulmonary disease (COPD) by End User

        • Hospitals & Clinics

        • Homecare Settings

        • Others

      • Italy Outlook (USD Billion, 2018-2030)

      • Italy North America Chronic obstructive pulmonary disease (COPD) by Type

        • Emphysema

        • Chronic Bronchitis

      • Italy Chronic obstructive pulmonary disease (COPD) by Treatment

        • Metal Drugs

          • Bronchodilator Monotherapy

            • Short-Acting Beta2-Agonists (SABAs)

            • Long-Acting Beta2-Agonists (LABAs)

            • Anti-Inflammatory Drugs

              • Oral And Inhaled Corticosteroids

              • Anti-Leukotrienes

        • Surgery

          • Lung Volume Reduction Surgery (LVRS)

          • Lung Transplant

          • Bullectomy

          • Others

        • Oxygen Therapy

      • Italy Chronic obstructive pulmonary disease (COPD) by End User

        • Hospitals & Clinics

        • Homecare Settings

        • Others

      • Spain Outlook (USD Billion, 2018-2030)

      • Spain Chronic obstructive pulmonary disease (COPD) by Type

        • Emphysema

        • Chronic Bronchitis

      • Spain Chronic obstructive pulmonary disease (COPD) by Treatment

        • Metal Drugs

          • Bronchodilator Monotherapy

            • Short-Acting Beta2-Agonists (SABAs)

            • Long-Acting Beta2-Agonists (LABAs)

            •  

          • Anti-Inflammatory Drugs

            • Oral And Inhaled Corticosteroids

            • Anti-Leukotrienes

        • Surgery

          • Lung Volume Reduction Surgery (LVRS)

          • Lung Transplant

          • Bullectomy

          • Others

        • Oxygen Therapy

      • Spain Chronic obstructive pulmonary disease (COPD) by End User

        • Hospitals & Clinics

        • Homecare Settings

        • Others

      • Rest Of Europe Outlook (USD Billion, 2018-2030)

      • Rest Of Europe Chronic obstructive pulmonary disease (COPD) by Type

        • Emphysema

        • Chronic Bronchitis

      • Rest of Europe Chronic obstructive pulmonary disease (COPD) by Treatment

        • Metal Drugs

          • Bronchodilator Monotherapy

            • Short-Acting Beta2-Agonists (SABAs)

            • Long-Acting Beta2-Agonists (LABAs)

              Anti-Inflammatory Drugs

              • Oral And Inhaled Corticosteroids

              • Anti-Leukotrienes

        • Surgery

          • Lung Volume Reduction Surgery (LVRS)

          • Lung Transplant

          • Bullectomy

          • Others

        • Oxygen Therapy

      • Rest of Europe Chronic obstructive pulmonary disease (COPD) by End User

        • Hospitals & Clinics

        • Homecare Settings

        • Others

    • Asia-Pacific Outlook (USD Billion, 2018-2030)

      • Asia-Pacific Chronic obstructive pulmonary disease (COPD) by Type

        • Emphysema

        • Chronic Bronchitis

      • Asia-Pacific Chronic obstructive pulmonary disease (COPD) by Treatment

        • Metal Drugs

          • Bronchodilator Monotherapy

            • Short-Acting Beta2-Agonists (SABAs)

            • Long-Acting Beta2-Agonists (LABAs)

          • Anti-Inflammatory Drugs

            • Oral And Inhaled Corticosteroids

            • Anti-Leukotrienes

        • Surgery

          • Lung Volume Reduction Surgery (LVRS)

          • Lung Transplant

          • Bullectomy

          • Others

        • Oxygen Therapy

      • Asia-Pacific Chronic obstructive pulmonary disease (COPD) by End User

        • Hospitals & Clinics

        • Homecare Settings

        • Others

      • China Outlook (USD Billion, 2018-2030)

      • China Chronic obstructive pulmonary disease (COPD) by Type

        • Emphysema

        • Chronic Bronchitis

      • China Chronic obstructive pulmonary disease (COPD) by Treatment

        • Metal Drugs

          • Bronchodilator Monotherapy

            • Short-Acting Beta2-Agonists (SABAs)

            • Long-Acting Beta2-Agonists (LABAs)

          • Anti-Inflammatory Drugs

            • Oral And Inhaled Corticosteroids

            • Anti-Leukotrienes

        • Surgery

          • Lung Volume Reduction Surgery (LVRS)

          • Lung Transplant

          • Bullectomy

          • Others

        • Oxygen Therapy

      • China Chronic obstructive pulmonary disease (COPD) by End User

        • Hospitals & Clinics

        • Homecare Settings

        • Others

      • Japan Outlook (USD Billion, 2018-2030)

      • Japan Chronic obstructive pulmonary disease (COPD) by Type

        • Emphysema

        • Chronic Bronchitis

      • Japan Chronic obstructive pulmonary disease (COPD) by Treatment

        • Metal Drugs

          • Bronchodilator Monotherapy

            • Short-Acting Beta2-Agonists (SABAs)

            • Long-Acting Beta2-Agonists (LABAs)

          • Anti-Inflammatory Drugs

            • Oral And Inhaled Corticosteroids

            • Anti-Leukotrienes

        • Surgery

          • Lung Volume Reduction Surgery (LVRS)

          • Lung Transplant

          • Bullectomy

          • Others

        • Oxygen Therapy

      • Japan Chronic obstructive pulmonary disease (COPD) by End User

        • Hospitals & Clinics

        • Homecare Settings

        • Others

      • India Outlook (USD Billion, 2018-2030)

      • India Chronic obstructive pulmonary disease (COPD) by Type

        • Emphysema

        • Chronic Bronchitis

      • India Chronic obstructive pulmonary disease (COPD) by Treatment

        • Metal Drugs

          • Bronchodilator Monotherapy

            • Short-Acting Beta2-Agonists (SABAs)

            • Long-Acting Beta2-Agonists (LABAs)

          • Anti-Inflammatory Drugs

            • Oral And Inhaled Corticosteroids

            • Anti-Leukotrienes

        • Surgery

          • Lung Volume Reduction Surgery (LVRS)

          • Lung Transplant

          • Bullectomy

          • Others

        • Oxygen Therapy

      • India Chronic obstructive pulmonary disease (COPD) by End User

        • Hospitals & Clinics

        • Homecare Settings

        • Others

      • South Korea Outlook (USD Billion, 2018-2030)

      • South Korea Chronic obstructive pulmonary disease (COPD) by Type

        • Emphysema

        • Chronic Bronchitis

      • South Korea Chronic obstructive pulmonary disease (COPD) by Treatment

        • Metal Drugs

          • Bronchodilator Monotherapy

            • Short-Acting Beta2-Agonists (SABAs)

            • Long-Acting Beta2-Agonists (LABAs)

          • Anti-Inflammatory Drugs

            • Oral And Inhaled Corticosteroids

            • Anti-Leukotrienes

        • Surgery

          • Lung Volume Reduction Surgery (LVRS)

          • Lung Transplant

          • Bullectomy

          • Others

        • Oxygen Therapy

      • South Korea Chronic obstructive pulmonary disease (COPD) by End User

        • Hospitals & Clinics

        • Homecare Settings

        • Others

      • Australia Outlook (USD Billion, 2018-2030)

      • Australia Chronic obstructive pulmonary disease (COPD) by Type

        • Emphysema

        • Chronic Bronchitis

      • Australia Chronic obstructive pulmonary disease (COPD) by Treatment

        • Metal Drugs

          • Bronchodilator Monotherapy

            • Short-Acting Beta2-Agonists (SABAs)

            • Long-Acting Beta2-Agonists (LABAs)

          • Anti-Inflammatory Drugs

            • Oral And Inhaled Corticosteroids

            • Anti-Leukotrienes

        • Surgery

          • Lung Volume Reduction Surgery (LVRS)

          • Lung Transplant

          • Bullectomy

          • Others

        • Oxygen Therapy

      • Australia Chronic obstructive pulmonary disease (COPD) by End User

        • Hospitals & Clinics

        • Homecare Settings

        • Others

      • Rest of Asia-Pacific Outlook (USD Billion, 2018-2030)

      • Rest of Asia-Pacific Chronic obstructive pulmonary disease (COPD) by Type

        • Emphysema

        • Chronic Bronchitis

      • Rest of Asia-Pacific Chronic obstructive pulmonary disease (COPD) by Treatment

        • Metal Drugs

          • Bronchodilator Monotherapy

            • Short-Acting Beta2-Agonists (SABAs)

            • Long-Acting Beta2-Agonists (LABAs)

          • Anti-Inflammatory Drugs

            • Oral And Inhaled Corticosteroids

            • Anti-Leukotrienes

        • Surgery

          • Lung Volume Reduction Surgery (LVRS)

          • Lung Transplant

          • Bullectomy

          • Others

        • Oxygen Therapy

      • Rest of Asia-Pacific Chronic obstructive pulmonary disease (COPD) by End User

        • Hospitals & Clinics

        • Homecare Settings

        • Others

    • Rest of the World Outlook (USD Billion, 2018-2030)

      • Rest of the World Chronic obstructive pulmonary disease (COPD) by Type

        • Emphysema

        • Chronic Bronchitis

      • Rest of the World Chronic obstructive pulmonary disease (COPD) by Treatment

        • Metal Drugs

          • Bronchodilator Monotherapy

            • Short-Acting Beta2-Agonists (SABAs)

            • Long-Acting Beta2-Agonists (LABAs)

          • Anti-Inflammatory Drugs

            • Oral And Inhaled Corticosteroids

            • Anti-Leukotrienes

        • Surgery

          • Lung Volume Reduction Surgery (LVRS)

          • Lung Transplant

          • Bullectomy

          • Others

        • Oxygen Therapy

      • Rest of the World Chronic obstructive pulmonary disease (COPD) by End User

        • Hospitals & Clinics

        • Homecare Settings

        • Others

      • Middle East Outlook (USD Billion, 2018-2030)

      • Middle East Chronic obstructive pulmonary disease (COPD) by Type

        • Emphysema

        • Chronic Bronchitis

      • Middle East Chronic obstructive pulmonary disease (COPD) by Treatment

        • Metal Drugs

          • Bronchodilator Monotherapy

            • Short-Acting Beta2-Agonists (SABAs)

            • Long-Acting Beta2-Agonists (LABAs)

          • Anti-Inflammatory Drugs

            • Oral And Inhaled Corticosteroids

            • Anti-Leukotrienes

        • Surgery

          • Lung Volume Reduction Surgery (LVRS)

          • Lung Transplant

          • Bullectomy

          • Others

        • Oxygen Therapy

      • Middle East Chronic obstructive pulmonary disease (COPD) by End User

        • Hospitals & Clinics

        • Homecare Settings

        • Others

      • Africa Outlook (USD Billion, 2018-2030)

      • Africa Chronic obstructive pulmonary disease (COPD) by Type

        • Emphysema

        • Chronic Bronchitis

      • Africa Chronic obstructive pulmonary disease (COPD) by Treatment

        • Metal Drugs

          • Bronchodilator Monotherapy

            • Short-Acting Beta2-Agonists (SABAs)

            • Long-Acting Beta2-Agonists (LABAs)

          • Anti-Inflammatory Drugs

            • Oral And Inhaled Corticosteroids

            • Anti-Leukotrienes

        • Surgery

          • Lung Volume Reduction Surgery (LVRS)

          • Lung Transplant

          • Bullectomy

          • Others

        • Oxygen Therapy

      • Africa Chronic obstructive pulmonary disease (COPD) by End User

        • Hospitals & Clinics

        • Homecare Settings

        • Others

      • Latin America Outlook (USD Billion, 2018-2030)

      • Latin America Chronic obstructive pulmonary disease (COPD) by Type

        • Emphysema

        • Chronic Bronchitis

      • Latin America Chronic obstructive pulmonary disease (COPD) by Treatment

        • Metal Drugs

          • Bronchodilator Monotherapy

            • Short-Acting Beta2-Agonists (SABAs)

            • Long-Acting Beta2-Agonists (LABAs)

          • Anti-Inflammatory Drugs

            • Oral And Inhaled Corticosteroids

            • Anti-Leukotrienes

        • Surgery

          • Lung Volume Reduction Surgery (LVRS)

          • Lung Transplant

          • Bullectomy

          • Others

        • Oxygen Therapy

      • Latin America Chronic obstructive pulmonary disease (COPD) by End User

        • Hospitals & Clinics

        • Homecare Settings

        • Others

    Market Trends

    Chronic Obstructive Pulmonary Disease (COPD) Market Overview

    Chronic Obstructive Pulmonary Disease (COPD) Market Size was valued at USD 20.84 billion in 2023 and is projected to grow from USD 22.07 Billion in 2024 to USD 33.72 billion by 2032, exhibiting a compound annual growth rate (CAGR) of 4.82% during the forecast period (2024 - 2032). Rise in prevalence of CPOD across the globe and the increase in adoption of more effective combination therapy are driving the market growth.

    Chronic Obstructive Pulmonary Disease Market

    Breathing problems are caused by various lung diseases known as chronic obstructive pulmonary disease. The two main chronic obstructive pulmonary disorders categories are emphysema and chronic bronchitis. One of the main signs of COPD is difficulty breathing. One significant element anticipated to accelerate the development and customer demand of the chronic obstructive pulmonary disease industry is the increase in COPD cases among populations worldwide. Additionally, throughout the forecast period, the global market is anticipated to grow due to an increase in cigarette usage among young people and a general increase in public awareness of the benefits of using generic medications.

    Additionally, increased healthcare spending is offering facilities for COPD in developing nations, ...

    Market Segment Insights

    Smartphone Sensors Smartphone Type Insights

    The Smartphone Sensors market segmentation, based on smartphone type, includes standard smartphone, rugged smartphone, smartwatches, and other wearable. The standard smartphone segment dominated the market, accounting for the maximum market revenue. A smartphone is a mobile phone with a built-in computer and advanced features, such as web browsing and operating system, which are not associated with its counterpart. The rising mobile internet use, rising disposable income in developing countries, and high ownership of premium design smartphones are a few factors that are anticipated to grow smartphone sales. Smartphones are helped by a mobile operating system that offers advanced computing facilities. A smartphone can also work as a digital media player for uploading photos, videos, and music through a single interface.

    Smartphone Sensors Market, By Device Type Outlook, 2024 & 2035
    Get detailed insights about Chronic Obstructive Pulmonary Disease (COPD) Market

    Smartphone Sensors Manufacturer Insights

    The Smartphone Sensors market segmentation, based on the manufacturer, includes Apple Inc., Samsung Electronics, Huawei Technology, Xiaomi Inc., Oppo, Sony Corporation, HMD Global, and others. The Apple Inc. segment generated the most revenue due to its superior quality. Apple’s iPhone stands out over all other smartphones in the market. Apple Inc. is the market leader because they use more sensors in their devices to provide unique features. For Instance: Apple’s iPhone 12 uses a lidar for depth sensing, proximity for 3D touch, a gyroscope for compass, GPS, face ID for biometrics, auto-off, a barometer, a magnetometer for compass & GPS, and an ambient light sensor for auto-dimming displays. The better user experience, increased accessibility, and more security these sensors offer consumers to boost the segment‘s growth.

    Smartphone Sensors Application Insights

    The Smartphone Sensors market segmentation, based on the manufacturer, includes Apple Inc., Samsung Electronics, Huawei Technology, Xiaomi Inc., Oppo, Sony Corporation, HMD Global, and others. The Apple Inc. segment generated the most revenue due to its superior quality. Apple’s iPhone stands out over all other smartphones in the market. Apple Inc. is the market leader because they use more sensors in their devices to provide unique features. For Instance: Apple’s iPhone 12 uses a lidar for depth sensing, proximity for 3D touch, a gyroscope for compass, GPS, face ID for biometrics, auto-off, a barometer, a magnetometer for compass & GPS, and an ambient light sensor for auto-dimming displays. The better user experience, increased accessibility, and more security these sensors offer consumers to boost the segment‘s growth.

    Smartphone Sensors Regional Insights

    The Smartphone Sensors market segmentation, based on the manufacturer, includes Apple Inc., Samsung Electronics, Huawei Technology, Xiaomi Inc., Oppo, Sony Corporation, HMD Global, and others. The Apple Inc. segment generated the most revenue due to its superior quality. Apple’s iPhone stands out over all other smartphones in the market. Apple Inc. is the market leader because they use more sensors in their devices to provide unique features. For Instance: Apple’s iPhone 12 uses a lidar for depth sensing, proximity for 3D touch, a gyroscope for compass, GPS, face ID for biometrics, auto-off, a barometer, a magnetometer for compass & GPS, and an ambient light sensor for auto-dimming displays. The better user experience, increased accessibility, and more security these sensors offer consumers to boost the segment‘s growth.

    Smartphone Sensors Market, By Device Type Outlook, 2024 & 2035
    Get detailed insights about Smartphone Sensors Market

    Smartphone Sensors Price Insights

    The Smartphone Sensors market segmentation, based on price, includes USD 300 to USD 500, USD 100 to USD 300, above USD 500, and under USD 100. The USD 300 to USD 500 segment dominated the market revenue in the projected period. Most smartphones sold in medium-end devices have a sensor within this range. For instance: Nubia launched a new flagship Android device powered by the latest Snapdragon 8Gen 2CPU. The OEM has also specified that this gadget, which peculiarly seems to go by the name Z50 even though its processor was the z40 Pro, will compete with the Xiaomi 13 and iQOO11 series with cutting-edge LPDDR5X RAM and storage with the most recent UFS 4.0 spec.

    Get more detailed insights about Chronic Obstructive Pulmonary Disease (COPD) Market

    Key Players and Competitive Insights

    Leading market players are investing heavily in research and development to expand their product lines, which will help the Smartphone Sensors market, grow even more. Market participants are also undertaking various strategic activities to expand their footprint, with important market developments including new product launches, contractual agreements, mergers and acquisitions, higher investments, and collaboration with other organizations. To expand and survive in a more competitive and growing market climate, the Smartphone Sensors industry must offer cost-effective items.

    Manufacturing locally to minimize operational costs is one of the key business tactics manufacturers use in the Smartphone Sensors industry to benefit clients and increase the market sector. In recent years, the Smartphone Sensors industry has offered manufacturers some of the most significant advantages. Major players in the Smartphone Sensors market, including MS AG (Austria), Broadcom Inc. (US), DYNA IMAGE Corporation (China), Murata Electronics Oy (Finland), NEXT Biometrics Group ASA (Norway), Omron Corporation (Japan), Samsung Electronics Co. Ltd. (South Korea), Sony Corporation (Japan)., and others, are attempting to increase market demand by investing in research and development operations.

    Samsung is dedicated to abiding by local laws and regulations and enforcing a strict code of conduct for all employees. Samsung adheres to a straightforward business tent: to usage its technology and expertise to develop top-notch goods and services that make a more cultured world. Samsung provides a high importance on its people and technologies to do this. For Instance: In January 2023, Samsung Electronics launched its new MICRO LED, Neo QLED, and Samsung OLED product lines, along with lifestyle products and accessories, before CES® 2023.

    Apple Inc. is a multinational American technology business with its main office in Cupertino, California. According to revenue, Apple will be the top technological business in the world in 2022, with US $ 394.3 billion in sales. According to market capitalization, Apple is the largest corporation in the world as of March 2023. For Instance: In September 2022, the iPhone 14 and iPhone 14 Plus, which come in two sizes, 6.1 and 6.7 inches and include a smart design, camera upgrades, and game-changing new safety measures, were introduced by Apple. The iPhone 14 and iPhone 14 Plus have a powerful camera system that incorporates the primary and front TrueDepth cameras, the Ultra Wide camera for uncommon perspectives, and the photonic engine, an enhanced picture pipeline.

    Key Companies in the Smartphone Sensors market include

    MS AG (Austria)
    MS AG (Austria)
    MS AG (Austria)
    MS AG (Austria)
    MS AG (Austria)
    MS AG (Austria)
    MS AG (Austria)

    Industry Developments

    • September 2022: Comcast and Samsung Electronics announced their partnership to create 5G Radio Access Network (RAN) technologies to enhance 5G connection for Xfinity Mobile and Comcast Business Mobile users in Comcast service zones. Samsung will provide 5G RAN technology, and Comcast will deploy Citizens Broadband Radio Service (CBRS) and 600 MHz spectrum to provide 5G access to consumer and business users in the US.
    • October 2022: Huawei announced the release of the newest antenna solutions, including the Maxwell platform and the X2 antenna series, for the subsequent 5G antenna innovation stage. The new technologies speed up 5G deployment by improving antenna and setup capabilities.

    Market Segmentation

    Smartphone Type Outlook

    • Standard Smartphone
    • Rugged Smartphone
    • Smartwatches
    • Other Wearable

    Price Outlook

    • USD 300 to USD 500
    • USD 100 to USD 300
    • Above USD 500
    • Under USD 100

    Manufacturer Outlook

    • Apple Inc.
    • Samsung Electronics
    • Huawei Technology
    • Xiaomi Inc.
    • Oppo
    • Sony Corporation
    • HMD Global

    Application Outlook

    • High-Level
    • Mid-Level
    • Low-Level

    Manufacturer Outlook

    North America
    • US
    • Canada
    Europe
    • Germany
    • France
    • UK
    • Italy
    • Spain
    • Rest of Europe
    Asia-Pacific
    • China
    • Japan
    • India
    • Italy
    • Australia
    • South Korea
    • Rest of Asia-Pacific
    Rest of the World
    • Middle East
    • Africa
    • Latin America

    Report Scope

    Attribute/Metric Details
    Market Size 2023 USD 20.84 billion
    Market Size 2024 USD 22.07 billion
    Market Size 2032 USD 33.72 billion
    Compound Annual Growth Rate (CAGR) 4.82% (2024-2032)
    Base Year 2023
    Forecast Period 2024-2032
    Historical Data 2018 & 2020
    Forecast Units Value (USD Billion)
    Report Coverage Revenue Forecast, Competitive Landscape, Growth Factors, and Trends
    Segments Covered Type, Treatment Type, End User and Region
    Geographies Covered North America, Europe, Asia Pacific, and Rest of the World
    Countries Covered The U.S, Canada, Germany, France, UK, Italy, Spain, China, Japan, India, Australia, South Korea, and Brazil
    Key Companies Profiled AstraZeneca (UK), Abbott Laboratories (US), Dr. Reddy’s Laboratories Ltd (India), GlaxoSmithKline (UK), F. Hoffmann-La Roche Ltd (Switzerland), Almirall (Spain), Boehringer Ingelheim (Germany), Pfizer Inc. (US), Novartis AG (Switzerland), Astellas Pharma (Japan)
    Key Market Opportunities Increasing demand for home care therapeutic devices
    Key Market Dynamics Rise in prevalence of CPOD across the globe Increase in adoption of more effective combination therapy

    Market Highlights

    Author

    Aarti Dhapte
    Team Lead - Research

    She holds an experience of about 6+ years in market research and business consulting, working under the spectrum of information communication technology, telecommunications and semiconductor domains. aarti conceptualizes and implements a scalable business strategy and provides strategic leadership to the clients. her expertise lies in market estimation, competitive intelligence, pipeline analysis, customer assessment, etc.

    Leave a Comment

    Latest Comments

    John Doe
    john@example.com

    This is a great article! Really helped me understand the topic better.

    Posted on July 23, 2025, 10:15 AM
    Jane Smith
    jane@domain.com

    Thanks for sharing this. I’ve bookmarked it for later reference.

    Posted on July 22, 2025, 7:45 PM
    View All

    FAQs

    What was the value of the global chronic obstructive pulmonary disease (COPD) market in 2018?

    The valuation of the global chronic obstructive pulmonary disease (COPD) market had reached USD 10.7 BN in 2018.

    At what CAGR is the global chronic obstructive pulmonary disease (COPD) market projected to grow in the forecast period (2019-2025)?

    The global chronic obstructive pulmonary disease (COPD) market is projected to grow at approximately 4.2% CAGR during the assessment period (2019-2025).

    What are the major tailwinds pushing the growth of the global chronic obstructive pulmonary disease (COPD) market?

    Technological advancements and new product launches and increasing demand for home care therapeutic devices are the major tailwinds pushing the growth of the global chronic obstructive pulmonary disease (COPD) market.

    Which region holds the largest share in the global chronic obstructive pulmonary disease (COPD) market?

    North America holds the largest share in the global chronic obstructive pulmonary disease (COPD) market, followed by Europe and the Asia Pacific, respectively.

    Who are the top players in the global chronic obstructive pulmonary disease (COPD) market?

    AstraZeneca (UK), Abbott (USA), Dr. Reddy’s Laboratories Ltd (India), GSK (UK), F. Hoffmann-La Roche Ltd (Switzerland), Merck (USA), Pfizer Inc. (USA), and Novartis AG (Switzerland), are some of the major players operating in the chronic obstructive pulmonary disease (COPD) market.

    1. GLOBAL CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) MARKET SYNOPSIS, 2020-2027
    2. WESTERN EUROPE: CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) MARKET, BY COPD
    3. EASTERN EUROPE: CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) MARKET, BY TREATMENT
    4. ASIA-PACIFIC: CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) MARKET, BY COPD TYPE,
    5. MIDDLE EAST & AFRICA: CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) MARKET,
    6. MARKET STRUCTURE FOR THE GLOBAL CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) MARKET
    7. GLOBAL CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) MARKET SHARE, BY REGION, 2020
    8. WESTERN EUROPE: CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) MARKET SHARE, BY
    9. ASTELLAS PHARMA: REGIONAL REVENUE
    10. NOVARTIS AG: KEY FINANCIALS
    11. TEVA PHARMACEUTICAL INDUSTRIES LTD: SEGMENTAL REVENUE

    Chronic Obstructive Pulmonary Disease (COPD) Market Segmentation Chronic obstructive pulmonary disease (COPD) Type Outlook (USD Billion, 2018-2030)

    • Emphysema
    • Chronic Bronchitis

    Chronic obstructive pulmonary disease (COPD) Treatment Outlook (USD Billion, 2018-2030)

    • Drugs

      • Bronchodilator Monotherapy

        • Short-Acting Beta2-Agonists (SABAs)
        • Long-Acting Beta2-Agonists (LABAs)

      • Anti-Inflammatory Drugs

        • Oral And Inhaled Corticosteroids
        • Anti-Leukotrienes

    • Surgery

      • Lung Volume Reduction Surgery (LVRS)
      • Lung Transplant
      • Bullectomy
      • Others
    • Oxygen Therapy

    Chronic obstructive pulmonary disease (COPD) End User Outlook (USD Billion, 2018-2030)

    • Hospitals & Clinics
    • Homecare Settings
    • Others

    Chronic obstructive pulmonary disease (COPD) Regional Outlook (USD Billion, 2018-2030)

    • North America Outlook (USD Billion, 2018-2030)

      • North America Chronic obstructive pulmonary disease (COPD) by Type
        • Emphysema
        • Chronic Bronchitis
      • North America Chronic obstructive pulmonary disease (COPD) by Treatment

        • Metal Drugs

          • Bronchodilator Monotherapy

            • Short-Acting Beta2-Agonists (SABAs)
            • Long-Acting Beta2-Agonists (LABAs)

          • Anti-Inflammatory Drugs

            • Oral And Inhaled Corticosteroids
            • Anti-Leukotrienes

        • Surgery

          • Lung Volume Reduction Surgery (LVRS)
          • Lung Transplant
          • Bullectomy
          • Others
        • Oxygen Therapy
      • North America Chronic obstructive pulmonary disease (COPD) by End User
        • Hospitals & Clinics
        • Homecare Settings
        • Others

      • US Outlook (USD Billion, 2018-2030)

      • US Chronic obstructive pulmonary disease (COPD) by Type
        • Emphysema
        • Chronic Bronchitis
      • US Chronic obstructive pulmonary disease (COPD) by Treatment

        • Metal Drugs

          • Bronchodilator Monotherapy

            • Short-Acting Beta2-Agonists (SABAs)
            • Long-Acting Beta2-Agonists (LABAs)

          • Anti-Inflammatory Drugs

            • Oral And Inhaled Corticosteroids
            • Anti-Leukotrienes

        • Surgery

          • Lung Volume Reduction Surgery (LVRS)
          • Lung Transplant
          • Bullectomy
          • Others
        • Oxygen Therapy
      • US Chronic obstructive pulmonary disease (COPD) by End User
        • Hospitals & Clinics
        • Homecare Settings
        • Others

      • Canada Outlook (USD Billion, 2018-2030)

      • Canada Chronic obstructive pulmonary disease (COPD) by Type
        • Emphysema
        • Chronic Bronchitis
      • Canada Chronic obstructive pulmonary disease (COPD) by Treatment

        • Metal Drugs

          • Bronchodilator Monotherapy

            • Short-Acting Beta2-Agonists (SABAs)
            • Long-Acting Beta2-Agonists (LABAs)

          • Anti-Inflammatory Drugs

            • Oral And Inhaled Corticosteroids
            • Anti-Leukotrienes

        • Surgery

          • Lung Volume Reduction Surgery (LVRS)
          • Lung Transplant
          • Bullectomy
          • Others
        • Oxygen Therapy
      • Canada Chronic obstructive pulmonary disease (COPD) by End User
        • Hospitals & Clinics
        • Homecare Settings
        • Others

    • Europe Outlook (USD Billion, 2018-2030)

      • Europe Chronic obstructive pulmonary disease (COPD) by Type
        • Emphysema
        • Chronic Bronchitis
      • Europe Chronic obstructive pulmonary disease (COPD) by Treatment

        • Metal Drugs

          • Bronchodilator Monotherapy

            • Short-Acting Beta2-Agonists (SABAs)
            • Long-Acting Beta2-Agonists (LABAs)

          • Anti-Inflammatory Drugs

            • Oral And Inhaled Corticosteroids
            • Anti-Leukotrienes

        • Surgery

          • Lung Volume Reduction Surgery (LVRS)
          • Lung Transplant
          • Bullectomy
          • Others
        • Oxygen Therapy
      • Europe Chronic obstructive pulmonary disease (COPD) by End User
        • Hospitals & Clinics
        • Homecare Settings
        • Others

      • Germany Outlook (USD Billion, 2018-2030)

      • Germany Chronic obstructive pulmonary disease (COPD) by Type
        • Emphysema
        • Chronic Bronchitis
      • Germany Chronic obstructive pulmonary disease (COPD) by Treatment

        • Metal Drugs

          • Bronchodilator Monotherapy

            • Short-Acting Beta2-Agonists (SABAs)
            • Long-Acting Beta2-Agonists (LABAs)

          • Anti-Inflammatory Drugs

            • Oral And Inhaled Corticosteroids
            • Anti-Leukotrienes

        • Surgery

          • Lung Volume Reduction Surgery (LVRS)
          • Lung Transplant
          • Bullectomy
          • Others
        • Oxygen Therapy
      • Germany Chronic obstructive pulmonary disease (COPD) by End User
        • Hospitals & Clinics
        • Homecare Settings
        • Others

      • France Outlook (USD Billion, 2018-2030)

      • France Chronic obstructive pulmonary disease (COPD) by Type
        • Emphysema
        • Chronic Bronchitis
      • France Chronic obstructive pulmonary disease (COPD) by Treatment

        • Metal Drugs

          • Bronchodilator Monotherapy

            • Short-Acting Beta2-Agonists (SABAs)
            • Long-Acting Beta2-Agonists (LABAs)

          • Anti-Inflammatory Drugs

            • Oral And Inhaled Corticosteroids
            • Anti-Leukotrienes

        • Surgery

          • Lung Volume Reduction Surgery (LVRS)
          • Lung Transplant
          • Bullectomy
          • Others
        • Oxygen Therapy
      • France Chronic obstructive pulmonary disease (COPD) by End User
        • Hospitals & Clinics
        • Homecare Settings
        • Others

      • UK Outlook (USD Billion, 2018-2030)

      • UK Chronic obstructive pulmonary disease (COPD) by Type
        • Emphysema
        • Chronic Bronchitis
      • UK Chronic obstructive pulmonary disease (COPD) by Treatment

        • Metal Drugs

          • Bronchodilator Monotherapy

            • Short-Acting Beta2-Agonists (SABAs)
            • Long-Acting Beta2-Agonists (LABAs)

          • Anti-Inflammatory Drugs

            • Oral And Inhaled Corticosteroids
            • Anti-Leukotrienes

        • Surgery

          • Lung Volume Reduction Surgery (LVRS)
          • Lung Transplant
          • Bullectomy
          • Others
        • Oxygen Therapy
      • UK Chronic obstructive pulmonary disease (COPD) by End User
        • Hospitals & Clinics
        • Homecare Settings
        • Others

      • Italy Outlook (USD Billion, 2018-2030)

      • Italy North America Chronic obstructive pulmonary disease (COPD) by Type
        • Emphysema
        • Chronic Bronchitis
      • Italy Chronic obstructive pulmonary disease (COPD) by Treatment

        • Metal Drugs

          • Bronchodilator Monotherapy

            • Short-Acting Beta2-Agonists (SABAs)
            • Long-Acting Beta2-Agonists (LABAs)

            • Anti-Inflammatory Drugs

              • Oral And Inhaled Corticosteroids
              • Anti-Leukotrienes

        • Surgery

          • Lung Volume Reduction Surgery (LVRS)
          • Lung Transplant
          • Bullectomy
          • Others
        • Oxygen Therapy
      • Italy Chronic obstructive pulmonary disease (COPD) by End User
        • Hospitals & Clinics
        • Homecare Settings
        • Others

      • Spain Outlook (USD Billion, 2018-2030)

      • Spain Chronic obstructive pulmonary disease (COPD) by Type
        • Emphysema
        • Chronic Bronchitis
      • Spain Chronic obstructive pulmonary disease (COPD) by Treatment

        • Metal Drugs

          • Bronchodilator Monotherapy

            • Short-Acting Beta2-Agonists (SABAs)
            • Long-Acting Beta2-Agonists (LABAs)
            •  

          • Anti-Inflammatory Drugs

            • Oral And Inhaled Corticosteroids
            • Anti-Leukotrienes

        • Surgery

          • Lung Volume Reduction Surgery (LVRS)
          • Lung Transplant
          • Bullectomy
          • Others
        • Oxygen Therapy
      • Spain Chronic obstructive pulmonary disease (COPD) by End User
        • Hospitals & Clinics
        • Homecare Settings
        • Others

      • Rest Of Europe Outlook (USD Billion, 2018-2030)

      • Rest Of Europe Chronic obstructive pulmonary disease (COPD) by Type
        • Emphysema
        • Chronic Bronchitis
      • Rest of Europe Chronic obstructive pulmonary disease (COPD) by Treatment

        • Metal Drugs

          • Bronchodilator Monotherapy

            • Short-Acting Beta2-Agonists (SABAs)

            • Long-Acting Beta2-Agonists (LABAs)

              Anti-Inflammatory Drugs

              • Oral And Inhaled Corticosteroids
              • Anti-Leukotrienes

        • Surgery

          • Lung Volume Reduction Surgery (LVRS)
          • Lung Transplant
          • Bullectomy
          • Others
        • Oxygen Therapy
      • Rest of Europe Chronic obstructive pulmonary disease (COPD) by End User
        • Hospitals & Clinics
        • Homecare Settings
        • Others

    • Asia-Pacific Outlook (USD Billion, 2018-2030)

      • Asia-Pacific Chronic obstructive pulmonary disease (COPD) by Type
        • Emphysema
        • Chronic Bronchitis
      • Asia-Pacific Chronic obstructive pulmonary disease (COPD) by Treatment

        • Metal Drugs

          • Bronchodilator Monotherapy

            • Short-Acting Beta2-Agonists (SABAs)
            • Long-Acting Beta2-Agonists (LABAs)

          • Anti-Inflammatory Drugs

            • Oral And Inhaled Corticosteroids
            • Anti-Leukotrienes

        • Surgery

          • Lung Volume Reduction Surgery (LVRS)
          • Lung Transplant
          • Bullectomy
          • Others
        • Oxygen Therapy
      • Asia-Pacific Chronic obstructive pulmonary disease (COPD) by End User
        • Hospitals & Clinics
        • Homecare Settings
        • Others

      • China Outlook (USD Billion, 2018-2030)

      • China Chronic obstructive pulmonary disease (COPD) by Type
        • Emphysema
        • Chronic Bronchitis
      • China Chronic obstructive pulmonary disease (COPD) by Treatment

        • Metal Drugs

          • Bronchodilator Monotherapy

            • Short-Acting Beta2-Agonists (SABAs)
            • Long-Acting Beta2-Agonists (LABAs)

          • Anti-Inflammatory Drugs

            • Oral And Inhaled Corticosteroids
            • Anti-Leukotrienes

        • Surgery

          • Lung Volume Reduction Surgery (LVRS)
          • Lung Transplant
          • Bullectomy
          • Others
        • Oxygen Therapy
      • China Chronic obstructive pulmonary disease (COPD) by End User
        • Hospitals & Clinics
        • Homecare Settings
        • Others

      • Japan Outlook (USD Billion, 2018-2030)

      • Japan Chronic obstructive pulmonary disease (COPD) by Type
        • Emphysema
        • Chronic Bronchitis
      • Japan Chronic obstructive pulmonary disease (COPD) by Treatment

        • Metal Drugs

          • Bronchodilator Monotherapy

            • Short-Acting Beta2-Agonists (SABAs)
            • Long-Acting Beta2-Agonists (LABAs)

          • Anti-Inflammatory Drugs

            • Oral And Inhaled Corticosteroids
            • Anti-Leukotrienes

        • Surgery

          • Lung Volume Reduction Surgery (LVRS)
          • Lung Transplant
          • Bullectomy
          • Others
        • Oxygen Therapy
      • Japan Chronic obstructive pulmonary disease (COPD) by End User
        • Hospitals & Clinics
        • Homecare Settings
        • Others

      • India Outlook (USD Billion, 2018-2030)

      • India Chronic obstructive pulmonary disease (COPD) by Type
        • Emphysema
        • Chronic Bronchitis
      • India Chronic obstructive pulmonary disease (COPD) by Treatment

        • Metal Drugs

          • Bronchodilator Monotherapy

            • Short-Acting Beta2-Agonists (SABAs)
            • Long-Acting Beta2-Agonists (LABAs)

          • Anti-Inflammatory Drugs

            • Oral And Inhaled Corticosteroids
            • Anti-Leukotrienes

        • Surgery

          • Lung Volume Reduction Surgery (LVRS)
          • Lung Transplant
          • Bullectomy
          • Others
        • Oxygen Therapy
      • India Chronic obstructive pulmonary disease (COPD) by End User
        • Hospitals & Clinics
        • Homecare Settings
        • Others

      • South Korea Outlook (USD Billion, 2018-2030)

      • South Korea Chronic obstructive pulmonary disease (COPD) by Type
        • Emphysema
        • Chronic Bronchitis
      • South Korea Chronic obstructive pulmonary disease (COPD) by Treatment

        • Metal Drugs

          • Bronchodilator Monotherapy

            • Short-Acting Beta2-Agonists (SABAs)
            • Long-Acting Beta2-Agonists (LABAs)

          • Anti-Inflammatory Drugs

            • Oral And Inhaled Corticosteroids
            • Anti-Leukotrienes

        • Surgery

          • Lung Volume Reduction Surgery (LVRS)
          • Lung Transplant
          • Bullectomy
          • Others
        • Oxygen Therapy
      • South Korea Chronic obstructive pulmonary disease (COPD) by End User
        • Hospitals & Clinics
        • Homecare Settings
        • Others

      • Australia Outlook (USD Billion, 2018-2030)

      • Australia Chronic obstructive pulmonary disease (COPD) by Type
        • Emphysema
        • Chronic Bronchitis
      • Australia Chronic obstructive pulmonary disease (COPD) by Treatment

        • Metal Drugs

          • Bronchodilator Monotherapy

            • Short-Acting Beta2-Agonists (SABAs)
            • Long-Acting Beta2-Agonists (LABAs)

          • Anti-Inflammatory Drugs

            • Oral And Inhaled Corticosteroids
            • Anti-Leukotrienes

        • Surgery

          • Lung Volume Reduction Surgery (LVRS)
          • Lung Transplant
          • Bullectomy
          • Others
        • Oxygen Therapy
      • Australia Chronic obstructive pulmonary disease (COPD) by End User
        • Hospitals & Clinics
        • Homecare Settings
        • Others

      • Rest of Asia-Pacific Outlook (USD Billion, 2018-2030)

      • Rest of Asia-Pacific Chronic obstructive pulmonary disease (COPD) by Type
        • Emphysema
        • Chronic Bronchitis
      • Rest of Asia-Pacific Chronic obstructive pulmonary disease (COPD) by Treatment

        • Metal Drugs

          • Bronchodilator Monotherapy

            • Short-Acting Beta2-Agonists (SABAs)
            • Long-Acting Beta2-Agonists (LABAs)

          • Anti-Inflammatory Drugs

            • Oral And Inhaled Corticosteroids
            • Anti-Leukotrienes

        • Surgery

          • Lung Volume Reduction Surgery (LVRS)
          • Lung Transplant
          • Bullectomy
          • Others
        • Oxygen Therapy
      • Rest of Asia-Pacific Chronic obstructive pulmonary disease (COPD) by End User
        • Hospitals & Clinics
        • Homecare Settings
        • Others

    • Rest of the World Outlook (USD Billion, 2018-2030)

      • Rest of the World Chronic obstructive pulmonary disease (COPD) by Type
        • Emphysema
        • Chronic Bronchitis
      • Rest of the World Chronic obstructive pulmonary disease (COPD) by Treatment

        • Metal Drugs

          • Bronchodilator Monotherapy

            • Short-Acting Beta2-Agonists (SABAs)
            • Long-Acting Beta2-Agonists (LABAs)

          • Anti-Inflammatory Drugs

            • Oral And Inhaled Corticosteroids
            • Anti-Leukotrienes

        • Surgery

          • Lung Volume Reduction Surgery (LVRS)
          • Lung Transplant
          • Bullectomy
          • Others
        • Oxygen Therapy
      • Rest of the World Chronic obstructive pulmonary disease (COPD) by End User
        • Hospitals & Clinics
        • Homecare Settings
        • Others

      • Middle East Outlook (USD Billion, 2018-2030)

      • Middle East Chronic obstructive pulmonary disease (COPD) by Type
        • Emphysema
        • Chronic Bronchitis
      • Middle East Chronic obstructive pulmonary disease (COPD) by Treatment

        • Metal Drugs

          • Bronchodilator Monotherapy

            • Short-Acting Beta2-Agonists (SABAs)
            • Long-Acting Beta2-Agonists (LABAs)

          • Anti-Inflammatory Drugs

            • Oral And Inhaled Corticosteroids
            • Anti-Leukotrienes

        • Surgery

          • Lung Volume Reduction Surgery (LVRS)
          • Lung Transplant
          • Bullectomy
          • Others
        • Oxygen Therapy
      • Middle East Chronic obstructive pulmonary disease (COPD) by End User
        • Hospitals & Clinics
        • Homecare Settings
        • Others

      • Africa Outlook (USD Billion, 2018-2030)

      • Africa Chronic obstructive pulmonary disease (COPD) by Type
        • Emphysema
        • Chronic Bronchitis
      • Africa Chronic obstructive pulmonary disease (COPD) by Treatment

        • Metal Drugs

          • Bronchodilator Monotherapy

            • Short-Acting Beta2-Agonists (SABAs)
            • Long-Acting Beta2-Agonists (LABAs)

          • Anti-Inflammatory Drugs

            • Oral And Inhaled Corticosteroids
            • Anti-Leukotrienes

        • Surgery

          • Lung Volume Reduction Surgery (LVRS)
          • Lung Transplant
          • Bullectomy
          • Others
        • Oxygen Therapy
      • Africa Chronic obstructive pulmonary disease (COPD) by End User
        • Hospitals & Clinics
        • Homecare Settings
        • Others

      • Latin America Outlook (USD Billion, 2018-2030)

      • Latin America Chronic obstructive pulmonary disease (COPD) by Type
        • Emphysema
        • Chronic Bronchitis
      • Latin America Chronic obstructive pulmonary disease (COPD) by Treatment

        • Metal Drugs

          • Bronchodilator Monotherapy

            • Short-Acting Beta2-Agonists (SABAs)
            • Long-Acting Beta2-Agonists (LABAs)

          • Anti-Inflammatory Drugs

            • Oral And Inhaled Corticosteroids
            • Anti-Leukotrienes

        • Surgery

          • Lung Volume Reduction Surgery (LVRS)
          • Lung Transplant
          • Bullectomy
          • Others
        • Oxygen Therapy
      • Latin America Chronic obstructive pulmonary disease (COPD) by End User
        • Hospitals & Clinics
        • Homecare Settings
        • Others
    Infographic

    Free Sample Request

    Kindly complete the form below to receive a free sample of this Report

    Related Reports

    Global Reports
    Regional Reports
    Country Reports

    Customer Strories

    Watch Video

    “I am very pleased with how market segments have been defined in a relevant way for my purposes (such as "Portable Freezers & refrigerators" and "last-mile"). In general the report is well structured. Thanks very much for your efforts.”

    Jongwon Byun

    Director, Research Operations
    Case Study

    Smartphone Motherboard Parts Manufacturing Research

    Smartphone Motherboard Parts Manufacturing Research